Date: 2014-02-17
Type of information: Capital increase
Company: Advanced Accelerator Applications (France)
Investors: Tamburi Investment Partners Group (Italy), HBM Healthcare Investments (Switzerland)
Amount: €41 million
Funding type: capital increase
Planned used: This capital increase will help fund expansion of AAA\'s activities in the US and finance clinical trials of its portfolio of MNM diagnostic and therapeutic products. This portfolio includes Lu-DOTATATE (Lutathera®), which is currently in phase III clinical trials for the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumors (an Orphan disease) in 51 clinical centers in the US and EU. Lutathera® is a theragnostic drug, because it integrates diagnostic and therapeutic properties into the same compound, allowing physicians to evaluate and monitor its efficacy using imaging at every therapeutic injection, without any additional costs.
Others: * On February 17, 2014, Advanced Accelerator Applications (AAA), a specialist in molecular nuclear medicine (MNM), has announced that it had successfully completed a capital increase of €41 million. The fundraising came from existing and new shareholders, including private investors and funds such as a company of the Tamburi Investment Partners Group and the specialist biotech and pharma investment company HBM Healthcare Investments Ltd who led the investment with €20 million.
AAA\'s portfolio includes Lu-DOTATATE (Lutathera®), which is currently in phase III clinical trials for the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumors (an Orphan disease) in 51 clinical centers in the US and EU.
AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada). In 2013 AAA is expecting to reach revenues of €56.6 million (+27% vs. 2012) and EBITDA of €14 million (+49% vs. 2012).
Therapeutic area: Diagnostic - Cancer - Oncology
